1144.5000 1.90 (0.17%)
NSE May 19, 2025 15:31 PM
Volume: 139.1K
 

1144.50
0.17%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Alivus Life Sciences Ltd. has gained 15.71% in the last 1 Month
More from Alivus Life Sciences Ltd.
Recommended